Skip to main content
. 2019 Jul 25;7:119. doi: 10.1186/s40478-019-0774-7

Fig. 4.

Fig. 4

Efficacy of combined treatment against subcutaneous and intracranial xenograft models. In the combined treatment group, tumor volume was significantly suppressed relative to the control group. (n = 4, error bars represent ± SEM, **p = 0.0021, p < 0.0001; Two-way ANOVA) (a). Representative macro and micro images of the tumors from mice implanted subcutaneously with NGT41 cells (b). Western blot analysis demonstrated that expression of phosphorylated ERK was drastically inhibited by the combined treatment (c). Combined dabrafenib and trametinib treatment significantly prolonged the survival of mice in the intracranial model relative to the control (p = 0.0299, Log Rank test) (d). Scale bars a: 10 mm; b: 50 μm